UPDATE: Roth Capital Upgrades ImmunoCellular Therapeutics (IMUC) to Buy
Tweet Send to a Friend
(Updated - June 2, 2014 9:23 AM EDT)
Roth Capital upgraded ImmunoCellular Therapeutics (NYSE: IMUC) from Neutral to Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Roth Capital upgraded ImmunoCellular Therapeutics (NYSE: IMUC) from Neutral to Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE